Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hematologic neoplasms characterized by the rearrangement of the FGFR1 gene, resulting in translocations with an 8p11 breakpoint. Patients present with a myeloproliferative neoplasm, acute myeloid leukemia, lymphoblastic lymphoma/leukemia of T or B-cell lineage, or acute leukemia of mixed phenotype.
Myeloid neoplasm associated with FGFR1 rearrangement is included in newborn screening programs (2-Methylbutyryl-CoA Dehydrogenase Deficiency) in 27 states.
No clinical trials have been registered for myeloid neoplasm associated with FGFR1 rearrangement.
15 publications have been identified in PubMed for myeloid neoplasm associated with FGFR1 rearrangement. Research spans Case Report / Case Series (53%), Review / Meta-Analysis (20%), and Clinical Trial Publication (7%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 8 | 53% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 10:51 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
3 |
20% |
Clinical study results | 1 | 7% |
Laboratory research | 1 | 7% |
Disease patterns and progression | 1 | 7% |
New treatment approaches | 1 | 7% |
Wu M (2025). [PMID: 41361549](https://pubmed.ncbi.nlm.nih.gov/41361549/). *Annals of hematology*. [Case Report / Case Series]
Al-Bazaz M (2025). [PMID: 41180818](https://pubmed.ncbi.nlm.nih.gov/41180818/). *Case reports in hematology*. [Case Report / Case Series]
Ito K (2025). [PMID: 40582839](https://pubmed.ncbi.nlm.nih.gov/40582839/). *Journal of clinical and experimental hematopathology : JCEH*. [Case Report / Case Series]
Verstovsek S (2025). [PMID: 40856555](https://pubmed.ncbi.nlm.nih.gov/40856555/). *NEJM evidence*. [Clinical Trial Publication]
Feng X (2025). [PMID: 41266899](https://pubmed.ncbi.nlm.nih.gov/41266899/). *Journal of hematopathology*. [Case Report / Case Series]
Chen X (2025). [PMID: 40586868](https://pubmed.ncbi.nlm.nih.gov/40586868/). *Annals of hematology*. [Case Report / Case Series]
Huang A (2025). [PMID: 40881645](https://pubmed.ncbi.nlm.nih.gov/40881645/). *Precision oncogenomics*. [Gene Therapy / Novel Therapeutics]
Lv M (2025). [PMID: 40762256](https://pubmed.ncbi.nlm.nih.gov/40762256/). *The Journal of international medical research*. [Basic Science / Preclinical]
Parasuraman S (2025). [PMID: 40618748](https://pubmed.ncbi.nlm.nih.gov/40618748/). *Acta haematologica*. [Epidemiology / Natural History]
Merenda E (2025). [PMID: 40474715](https://pubmed.ncbi.nlm.nih.gov/40474715/). *Pathologica*. [Case Report / Case Series]